165 related articles for article (PubMed ID: 22204341)
1. Targeting ion channels in leukemias: a new challenge for treatment.
Arcangeli A; Pillozzi S; Becchetti A
Curr Med Chem; 2012; 19(5):683-96. PubMed ID: 22204341
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
3. Physical and functional interaction between integrins and hERG1 channels in cancer cells.
Pillozzi S; Arcangeli A
Adv Exp Med Biol; 2010; 674():55-67. PubMed ID: 20549940
[TBL] [Abstract][Full Text] [Related]
4. Role of hERG1 K(+) channels in leukemia cells as a positive regulator in SDF-1a-induced proliferation.
Zheng F; Li H; Du W; Huang S
Hematology; 2011 May; 16(3):177-84. PubMed ID: 21669058
[TBL] [Abstract][Full Text] [Related]
5. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome.
Pillozzi S; Brizzi MF; Bernabei PA; Bartolozzi B; Caporale R; Basile V; Boddi V; Pegoraro L; Becchetti A; Arcangeli A
Blood; 2007 Aug; 110(4):1238-50. PubMed ID: 17420287
[TBL] [Abstract][Full Text] [Related]
6. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors.
Pillozzi S; Brizzi MF; Balzi M; Crociani O; Cherubini A; Guasti L; Bartolozzi B; Becchetti A; Wanke E; Bernabei PA; Olivotto M; Pegoraro L; Arcangeli A
Leukemia; 2002 Sep; 16(9):1791-8. PubMed ID: 12200695
[TBL] [Abstract][Full Text] [Related]
7. The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF-1 in acute leukemic cell migration.
Li H; Du YM; Guo L; Jie S; Zhang S; Du W; Chen X; Liu W; Fan L; Zhu J; Zou A; Huang S
Exp Cell Res; 2009 Aug; 315(13):2256-64. PubMed ID: 19409379
[TBL] [Abstract][Full Text] [Related]
8. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy.
Arcangeli A; Crociani O; Lastraioli E; Masi A; Pillozzi S; Becchetti A
Curr Med Chem; 2009; 16(1):66-93. PubMed ID: 19149563
[TBL] [Abstract][Full Text] [Related]
9. Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow‑induced chemoresistance in acute leukemias.
Pillozzi S; Bernini A; Spiga O; Lelli B; Petroni G; Bracci L; Niccolai N; Arcangeli A
Oncol Rep; 2019 Jan; 41(1):312-324. PubMed ID: 30365110
[TBL] [Abstract][Full Text] [Related]
10. Human ether-a-go-go-related gene K+ channels regulate shedding of leukemia cell-derived microvesicles.
Zheng F; Li J; Du W; Wang N; Li H; Huang S
Leuk Lymphoma; 2012 Aug; 53(8):1592-8. PubMed ID: 22292854
[TBL] [Abstract][Full Text] [Related]
11. Novel perspectives in cancer therapy: Targeting ion channels.
Arcangeli A; Becchetti A
Drug Resist Updat; 2015; 21-22():11-9. PubMed ID: 26183291
[TBL] [Abstract][Full Text] [Related]
12. Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung C; Ma H
Pharmacotherapy; 2017 Sep; 37(9):1052-1072. PubMed ID: 28654205
[TBL] [Abstract][Full Text] [Related]
13. Expression and functional role of HERG1, K+ channels in leukemic cells and leukemic stem cells.
Li H; Liu L; Guo T; Zhang J; Li X; Du W; Liu W; Chen X; Huang S
J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):257-60. PubMed ID: 17641836
[TBL] [Abstract][Full Text] [Related]
14. Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation.
Shipounova IN; Petinati NA; Bigildeev AE; Drize NJ; Sorokina TV; Kuzmina LA; Parovichnikova EN; Savchenko VG
Leuk Lymphoma; 2017 Feb; 58(2):408-417. PubMed ID: 27244369
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
16. Therapeutically Targetable ALK Mutations in Leukemia.
Maxson JE; Davare MA; Luty SB; Eide CA; Chang BH; Loriaux MM; Tognon CE; Bottomly D; Wilmot B; McWeeney SK; Druker BJ; Tyner JW
Cancer Res; 2015 Jun; 75(11):2146-50. PubMed ID: 26032424
[TBL] [Abstract][Full Text] [Related]
17. Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid.
Verdonck LF; Witteveen EO; van Heugten HG; Rozemuller E; Rijksen G
Cancer Res; 1990 Jul; 50(13):4020-5. PubMed ID: 2354451
[TBL] [Abstract][Full Text] [Related]
18. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
20. [Morphological, immunological and cytogenetic diagnosis in acute leukemias].
Ratei R; Sperling C; Ludwig WD
Ther Umsch; 1996 Feb; 53(2):88-96. PubMed ID: 8629269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
